From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

Last Updated: Monday, April 25, 2022

This case series describes the use of early intrathecal steroid administration to manage high-grade and steroid-refractory immune effector cell-associated neurotoxicity syndrome among patients with B-cell non-Hodgkin lymphoma.

JAMA Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement